Effect of Meropenem-Vaborbactam vs Piperacillin-Tazobactam on Clinical Cure or Improvement and Microbial Eradication in Complicated Urinary Tract Infection: The TANGO I Randomized Clinical Trial

IMPORTANCE: Meropenem-vaborbactam is a combination carbapenem/beta-lactamase inhibitor and a potential treatment for severe drug-resistant gram-negative infections. OBJECTIVE: To evaluate efficacy and adverse events of meropenem-vaborbactam in complicated urinary tract infection (UTI), including acu...

תיאור מלא

שמור ב:
מידע ביבליוגרפי
הוצא לאור ב:JAMA
Main Authors: Kaye, Keith S., Bhowmick, Tanaya, Metallidis, Symeon, Bleasdale, Susan C., Sagan, Olexiy S., Stus, Viktor, Vazquez, Jose, Zaitsev, Valerii, Bidair, Mohamed, Chorvat, Erik, Dragoescu, Petru Octavian, Fedosiuk, Elena, Horcajada, Juan P., Murta, Claudia, Sarychev, Yaroslav, Stoev, Ventsislav, Morgan, Elizabeth, Fusaro, Karen, Griffith, David, Lomovskaya, Olga, Alexander, Elizabeth L., Loutit, Jeffery, Dudley, Michael N., Giamarellos-Bourboulis, Evangelos J.
פורמט: Artigo
שפה:Inglês
יצא לאור: American Medical Association 2018
נושאים:
Original Investigation
גישה מקוונת:https://ncbi.nlm.nih.gov/pmc/articles/PMC5838656/
https://ncbi.nlm.nih.gov/pubmed/29486041
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1001/jama.2018.0438
תגים: הוספת תג
אין תגיות, היה/י הראשונ/ה לתייג את הרשומה!

פריטים דומים